December 26, 2016
(Managed Care Magazine) – In a new report, the Senate’s Special Committee on Aging examines the business model used by these companies; assesses the impacts of price hikes on patients, payers, providers, hospitals, and governments; and discusses potential policy responses. The committee discovered that each of the four companies followed a business model that enabled them to identify and acquire off-patent sole-source drugs, over which they could exercise de facto monopoly pricing power, and then impose and protect huge price increases. The business model consists of five central elements.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.